Aura Biosciences, Inc. Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Aura Biosciences, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2026-03-31 was $121.00K, a 26.04% increase year-over-year.
- Aura Biosciences, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-09-30 was $68.00K, a 17.07% decline year-over-year.
- Aura Biosciences, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-03-31 was $96.00K, a 1.05% increase year-over-year.
- Aura Biosciences, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2024-09-30 was $82.00K, a 13.89% increase year-over-year.
- Aura Biosciences, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2025 was $164.00K, a 7.34% decline from fiscal 2024.
- Aura Biosciences, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2024 was $177.00K, a 38.28% increase from fiscal 2023.
- Aura Biosciences, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2023 was $128.00K.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2026-03-31 | $121.00K 10-Q · filed 2026-08-11 | |
| 2025-12-31 | $164.00K 10-K · filed 2026-03-30 | |
| 2025-09-30 | $68.00K 10-Q · filed 2025-11-13 | |
| 2025-03-31 | $96.00K 10-Q · filed 2026-08-11 | |
| 2024-12-31 | $177.00K 10-K · filed 2026-03-30 | |
| 2024-09-30 | $82.00K 10-Q · filed 2025-11-13 | |
| 2024-03-31 | $95.00K 10-Q · filed 2025-11-13 | |
| 2023-12-31 | $128.00K 10-K · filed 2025-03-24 | |
| 2023-09-30 | $72.00K 10-Q · filed 2024-11-12 | |
| 2023-03-31 | $56.00K 10-Q · filed 2024-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |